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Inosine-5'-monophosphate dehydrogenase (IMPDH)
activity and mRNA levels are induced up to IS-fold upon
mitogenic or antigenic stimulation of human peripheral
blood T lymphocytes. This increase in IMPDH activity is
required for cellular proliferation and has been associ-
ated with malignant transformation. We have cloned the
human IMPDH type II gene and show that it contains 14
exons and is approximately 5.8 kilobases in length. Ex-
ons vary in size from 49 to 207 base pairs and introns
from 73 to 1065 base pairs. The transcription start site
was mapped to a position 50 nucleotides upstream ofthe
translation initiation site. The 5' -flanking region con-
sisting of 463 base pairs upstream of the translation
initiation site confers induced transcription and differ-
ential regulation upon a chloramphenicol acetyltrans-
ferase reporter gene when transfected into Jurkat T
cells and human peripheral blood T lymphocytes, re-
spectively. DNase I footprinting analysis using Jurkat T
cell nuclear extract identified four protected regions in
the promoter which coincide with consensus transcrip-
tion factor binding sites for the nuclear factors AP2,
ATF, CREB, Egr-L, Nm23, and Spl. These findings sug-
gest that several of these nuclear factors may play a
critical role in the regulation of IMPDH type II gene
expression during T lymphocyte activation.
Inosine-5'-monophosphate dehydrogenase (IMPDH,l EC
1.1.1.205) is positioned at the branch point of adenine and
guanine nucleotide biosynthesis from IMP and constitutes the
rate-limiting enzyme in the de novo synthesis of guanine nu-
cleotides. The enzyme catalyses the NAD-dependent oxidation
of IMP to XMP and is responsible for maintaining cellular
guanine deoxy- and ribonucleotide pools required for DNA and
RNA biosynthesis, respectively. Enzyme activity varies with
the cell cycle, exhibiting maximal activity in S phase (1).
Total cellular IMPDH activity is accounted for by the expres-
sion of two distinct genes, IMPDH type I located on chromo-
some 7 and IMPDH type II located on chromosome 3 (2, 3). The
human IMPDH type I and type II cDNAs have been isolated
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and found to contain open reading frames encoding 514 amino
acid proteins of 56 kilodaltons (4, 5). These enzymes are 84%
identical at the amino acid level and demonstrate very similar
kinetic parameters (4, 6, 7).
The close correlation between elevated IMPDH activity and
cell proliferation and the observation of high activity in neo-
plastic cells have linked IMPDH activity to malignant trans-
formation (8, 9). This association has led to the search for and
development of several inhibitors with demonstrated antineo-
plastic and immunosuppressive potential (10, 11). Such inhib-
itors of IMPDH activity have been demonstrated to inhibit cell
proliferation and induce cellular differentiation as a conse-
quence of the reduction of guanine nucleotide levels (12-16).
Regulation of IMPDH activity during cellular growth and
differentiation has been largely attributed to changes in the
expression of the IMPDH type II gene. The type II 2.3-kb
mRNA transcript is the predominant species in neoplastic cells
and is selectively up-regulated in replicating cells (17-19). Con-
versely, when neoplastic cells are induced to differentiate, the
enhanced levels of the type II transcript and total cellular
activity are down-regulated (13-15). In contrast, the 3.5-kb
type I transcript remains constitutively expressed during cell
proliferation and induction of cell differentiation (4, 17-19).
The modulation of cellular IMPDH activity during cell growth
and differentiation suggests a critically important role for the
regulation ofIMPDH type II gene expression in the progression
of normal cell development. In order to assess the molecular
mechanisms governing the expression of IMPDH type II in
quiescent, replicating, and differentiating cells, we have cloned
the IMPDH type II gene and characterized the gene and its
5' -flanking region.
MATERlALS AND METHODS
Cloning ofIMPDH Type II Genomic DNA-A human genomic library
established in A-FIX by partial BglI digestion of human leukocyte DNA
followed by ligation into the phage DNA vector was provided by Dr. J.
Lowe (University of Michigan, Ann Arbor). Approximately 7 x 105
plaques were screened using full-length IMPDH type II cDNA,provided
by Dr. F. Collart (Argonne National Laboratory, Argonne, IL). The
cDNA was labeled with [a_32P]dCTP (3000 Ci/mmol; Amersham Corp.)
using DNA polymerase large fragment (New England Biolabs Inc.),
Unincorporated nucleotides were removed by ethanol precipitation.
Hybridization was performed in 2 x SSC, 1%SDS, 10%dextran sulfate,
and 50% formamide at 42°C for 24 h after which the filters were
washed with 1 x SSC, 0.1% SDS at 65°C. Two positive phage clones of
approximately 15 kb were identified, plaque-purified, and characterized
by restriction endonuclease mapping. Sad fragments from a single
insert were subcloned into the vector pGEM7Zf\+) and analyzed by
Southern blotting. Positive clones containing 4.8- and 6.8-kb inserts
were further analyzed by restriction mapping and sequenced according
to the Sanger dideoxy chain termination method (20) using eDNA,
intron, and vector primers.
Plasmid Constructs-pBSCAT was derived from the pBS vector by
cloning the chloramphenicol acetyltransferase (CAT) eDNA into the
BamHI site. Employing a 5' probe spanning nucleotides 90-126 of the
IMPDH type II cDNA (5), a 1536-bp EcoRI fragment containing the 5'
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region of the gene was identified within the 4.8-kb Sac! fragment. This
fragment was subcloned into pGEM7Ztl:+) and sequenced on both
strands. The fragment spanning bp -463 to + 1073 relative to the A
(+ 1) of the translation start site was reisolated using EcoRl, cloned
into the Sall site of the vector pBSCAT, and designated
pBS1536(5'~3')CAT.A 466-bp genomic fragment containing the 5'-
flanking region extending from EcoRl to a Ncol site at the ATG initia-
tion codon of the first exon (bp -463 to +3; Fig. 1) was excised from the
1536-bp EcoRl pGEM7Ztl:+) construct using the vector Pstl and
genomic Ncol sites and subcloned into pBSCAT in the 3' ~5' orientation
relative to the CAT reporter gene (designated pBS466(3'~5')CAT).The
identical fragment was subcloned into the Smal site of pGEM7Ztl:+ ),
removed by a XbaIlHindlU restriction digest, and subcloned into the
identical sites of pBSCAT to obtain the 5' ~3' orientation (designated
pBS466(5'~3')CAT).
Primer Extension Analysis-Primer extension analysis was per-
formed with the Primer Extension System (Prornega, Madison, WI)
employing 5 I'-gof poly(A+) Jurkat T cell RNA and the reverse comple-
mentary oligonucleotide 5'-GTT GAA GAG CTG CTG TGC TGT GAG
TC-3' that anneals to the region extending from +49 to +75 relative to
the translation initiation site (5). Briefly, 100 ng of oligonucleotide
primer was end-labeled with [y_32p IATP using T4 polynucleotide ki-
nase. Approximately 1 ng of labeled primer was added to 5 I'-gof RNA
in the presence of 2 x primer extension buffer. The primer was an-
nealed to the RNA at 58°C for 20 min followed by cooling to room
temperature for 30 min. The annealed primer was extended with avian
myeloblastoma virus reverse transcriptase at 42°C for 30 min and
ethanol-precipitated using 20 I'-g of carrier tRNA. Following precipita-
tion, the sample was resuspended in 6 1'-1 of gel loading dye, and 3 1'-1
were analyzed on a denaturing 8 Murea, 6% polyacrylamide gel. The gel
was fixed, dried, and autoradiographed overnight at -70°C.
RNase A Protection Assay-RNase A protection analysis was per-
formed using the pGEM7Ztl:+ )-466bp construct that extends 463 bp
upstream of and includes the translation initiation site. The vector was
linearized at the 5' end of the insert with the restriction enzyme
HindUl, and transcribed in vitro from the T7 RNA polymerase pro-
moter to generate a [32pICTP-labeled antisense RNA transcript. The
assay was performed using the Ambion ribonuclease protection assay
kit (Ambion, Austin, TX). Five I'-gofpoly(A+) Jurkat T, HL60, and Raji
cell RNA were precipitated with 5 x 105 cpm of probe and resuspended
in 20 1'-1 of hybridization buffer. Samples were denatured at 95°C for 3
min and then incubated at 42 °C for 18 h. Following hybridization, 200
1'-1 of RNase digestion buffer containing RNase A and RNase T1 were
added, and the samples were incubated at 37°C for 30 min. RNA was
subsequently precipitated, resuspended in gel loading buffer, and sep-
arated on a 8 Murea, 6% polyacrylamide gel. The gel was fixed, dried,
and autoradiographed overnight at -70°C.
Isolation of Peripheral Blood T Lymphocytes-Buffy coats from nor-
mal donors were obtained from the American Red Cross, and the mono-
nuclear cells were isolated by density gradient centrifugation using
Histopaque 1077 (Sigma) (21). Cells at the interface were removed,
washed with PBS, and resuspended in RPMl 1640 medium containing
10% heat-inactivated fetal calf serum. Monocytes were depleted by
culture dish adherence and B lymphocytes by negative selection using
an anti-CD20 antibody (Coulter Corp., Hialeah, FL). Flow cytometric
analysis of the isolated T lymphocytes with an anti-Cfrz" marker
revealed a greater than 95% enrichment of CD2+ T cells. Cellular
[3Hlthymidine incorporation into DNA from resting and activated cells
was determined as a measure of proliferative activity.
Transient Transfections-ln order to study the promoter activity of
the lMPDH type U 5'-flanking sequence, each CAT-reporter construct
(30 I'-g) was transfected into 1 x 107 exponentially growing Jurkat T
cells or 2 X 107 isolated peripheral blood T lymphocytes prestimulated
according to the protocol of Park et al. (22). A f3-actin-f3-galactosidase
(pf3Ac-lacZ)construct was used in Jurkat T cells to determine transfec-
tion efficiency (23). Jurkat T lymphoblasts and peripheral blood T
lymphocytes were maintained in RPMl 1640 medium supplemented
with 2 mM L-glutamine, 100 units/ml penicillin, 100 I'-g/ml streptomy-
cin, and 10% fetal calf serum for the Jurkat T cells and 10% heat-
inactivated fetal calf serum for the T lymphocytes, respectively (Hy-
clone Labs, Logan, UT). Cells were cultured at 37°C in a humidified
atmosphere in the presence of 5% CO2, Electroporations were per-
formed at room temperature in the presence of culture medium using a
Bio-Rad Gene Pulser with settings of 250 Vl960 I'-F for Jurkat T cells
and 350 V/960 I'-F for T lymphocytes. Transfected Jurkat T cells were
cultured for 48 h, harvested, washed three times with phosphate-buff-
ered saline (PBS), resuspended in 150 1'-1 of 0.25 M Tris-HCl (pH 8.0),
and extracted with three cycles of freeze-thawing. Transfected periph-
eral blood T lymphocytes were incubated for 18 h prior to phorbol
12-myristate 13-acetate (PMA) (10 ng/ml) and ionomycin (125 ng/ml)
treatment. The cells were maintained in culture for 48 h and then
processed as described above for Jurkat T cells. Cleared supernatants
obtained after spinning extracts at 16,000 x g for 10 min were used for
protein and f3-galactosidase activity assays. Aliquots were heated to
60°C for 10 min followed by centrifugation at 16,000 x g for 10 min.
The supernatants were assayed with 0.1 I'-Ci of [14Clchloramphenicol
and 25 I'-gof n-butyryl-CoA for 1-6 h, extracted with xylenes according
to the Promega CAT enzyme assay system, and analyzed by liquid
scintillation counting. Protein concentrations were determined with the
Bio-Rad protein assay according to the method of Bradford (24).
Nuclear Extracts-Extracts were made from logarithmically growing
Jurkat T cells according to the method of Dignam et al. (25) with
modifications as described by Blake et al. (26). Cells were homogenized
in buffer A (10 mM HEPES, pH 7.9, 0.75 mM spermidine, 0.15 mM
spermine, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM DTT, 1 mM
PMSF), and nuclei were recovered by centrifugation at 30,000 x g for 30
s. Nuclear factors were extracted in buffer C (20 mM HEPES, pH 7.9, 0.2
mMEDTA, 0.2 mM EGTA, 2 mx DTT, 20% glycerol, 0.15 mM spermine,
0.75 mM spermidine, 1 mM PMSF, 0.4 MNaC!), followed by centrifuga-
tion at 300,000 x g for 45 min. The supernatant was dialyzed in buffer
D (20 mM HEPES, pH 7.9, 20% glycerol, 100 mMKCl, 0.2 mMEDTA, 0.2
mM EGTA, 2 mv DTT, 1 mM PMSF, 12.5 mM MgCI2), aliquoted, and
stored at -70°C.
DNase I Footprinting-A probe covering the 466-bp promoter region
was prepared by Ncol digestion of the pBS466(5'~3')CATconstruct,
fill-in labeling with DNA polymerase large fragment, and digestion
with HindU!. The resulting fragments were separated on a 6% nonde-
naturing polyacrylamide gel, and the probe was excised and eluted by
the "crush and soak" method (27). DNase I footprinting was performed
according to Blake et al. (26). Ten ng op2P-labeled DNA were incubated
with 120 and 240 I'-gof Jurkat T cell nuclear extract in the presence of
15 I'-gofpoly(dl-dC), 6.1% glycerol, 0.07 mMEDTA, 0.07 mMEGTA, 7.2
mM HEPES, pH 7.9, 39 mM KCl, 7.5 mMMgC12' and 0.7 mM DTT. The
binding reactions were performed at room temperature for 30 min after
which CaCl2 (2 mM final concentration) was added, and the probe was
digested with DNase I (Worthington) at room temperature for 3 min.
Digestions were terminated by the addition of 2 volumes of 100 mv Tris,
pH 8.0,20 mMEDTA, 0.1% SDS, 100 ug/ml proteinase K, and 100 I'-g/ml
glycogen. After an incubation at 37°C for 20 min, the samples were
extracted with phenol/chloroform, precipitated with ethanol, resus-
pended in formamide loading dye, and analyzed on a 8 M urea, 6%
polyacrylamide sequencing gel.
RESULTS
Isolation of Type II Genomic DNA Clones-Genomic clones
were isolated by screening a human genomic A-FIXlibrary with
a 2.0-kb full-length IMPDH type II eDNA. Digestion of a single
genomic clone with Sac! resulted in fragments of 6.8, 4.8, 2.9,
1.5, and 0.8 kb that were subcloned into the vector
pGEM7Ztr + ) and analyzed by Southern blotting. The 4.8- and
6.8-kb fragments hybridized to the IMPDH type II eDNA. Se-
quence analysis revealed that the 4.8- and 6.8-kb fragments
contain the entire coding region of the type II gene as previ-
ously published by Collart and Huberman (5).
Structure ofthe IMPDH Type II Gene-Deoxyribonucleic acid
primers were used to sequence and map the exon-intron junc-
tions of the type II gene encompassed in both the 4.8- and
6.8-kb Sac! fragments. Exons 1 through 5 were located in the
4.8-kb Sac! fragment and exons 6 through 14 in the 6.8-kb Sac!
fragment. The following inconsistencies were found with re-
spect to the published cDNA sequence: a single base mismatch
(bp 2; G~C), the absence of 9 nucleotides (GTCTCTGCG) at
the 5' terminus of the eDNA, and 3 erroneous cytosine residues
(CCC~AAA)at the 3' terminus of the eDNA. In addition, two
consecutive cytosine residues at positions 608-609 are re-
placed by a single thymidine base at position 608 and a guanine
base between bp 613 and 614 of the eDNA. These substitutions
result in the conversion of arginine 110 and serine 111 to
alanine and glycine residues, respectively (5). To confirm that
the 4.8- and 6.8-kb Sac! fragments are contiguous, human
genomic DNA was subjected to polymerase chain reaction anal-
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FIG. 1. Schema and partial restriction map of the human 1M-
PDH type II gene. Restriction sites for Sac! and EcoRI are shown.
Exons are represented by open bars and intron and flanking sequences
by solid lines.
ysis using eDNA oligonucleotide primers 5'-AGGCCCGGCAT-
GGTTTC-3' (position 442-458) and 5' -AGGGGCTACCAC-
CAAGTCTTCCC-3' (position 586-608) (5) located in exons 5
and 6, respectively. The polymerase chain reaction product is a
700-bp fragment that corresponds to the size of the intervening
intron as determined by sequence analysis. The human IM-
PDH type II gene is therefore approximately 5.8 kb in length
and has 14 exons of 148,49, 102,75,207,88,200,91,96, 144,
145, 144, 84, and 75 bp interrupted by 13 introns (Fig. 1 and
Table I). All exon-intron boundaries contained the canonical
splice acceptor (GT) and donor (AG) consensus sequences
(Table I).
Mapping of the Transcription Start Sites-The transcription
start site of the IMPDH type II gene was identified by primer
extension analysis and confirmed by RNase A protection anal-
ysis. A single major primer extended product was identified at
a position 50 bp 5' to the A (+ 1) of the translation initiation
codon (Fig. 2A). RNase A protection analysis was performed
using the pBS466CAT genomic clone that contains the 463-bp
5'-flanking region and the 3-bp translation start site of the
gene. A complementary RNA transcript which extends 463
nucleotides 5' of the translation start site was synthesized and
hybridized to Jurkat T cell poly(A+) mRNA. RNase A digestion
resulted in a single protected fragment of approximately 59 bp
in the T cell lines Jurkat and HL60 and the B cell line Raji (Fig.
2B). This is in close agreement with the location of the tran-
scription start site identified by primer extension analysis.
Structural and Functional Analysis of the IMPDH Type II
Promoter-The 1536-bp EcoRI fragment located within the
4.8-kb Sad fragment was sequenced on both strands and found
to contain 463 bp of sequence 5' to the translation initiation
site, and downstream sequence extending to bp + 1073 in exon
4 (Fig. 3). The downstream EcoRI site corresponds with the
EcoRI site located at bp 334 in the eDNA (5). A computer-
assisted transcription factor data base search (Genetics Com-
puter Group, Madison, WI) ofthe 1536-bp genomic sequence for
putative nuclear protein binding sites revealed a cluster of
consensus motifs for DNA binding proteins in the 5' -flanking
region of the gene. As shown in Fig. 3, a TATA box is located at
bp -74 relative to the translation initiation site (28). Two
putative activator protein-2 (AP2) binding sites are located at
positions -133 and -163 (29), and three putative binding sites
for Sp1 are located at positions -137, -149, and -167 (30-32).
In addition, the sequence from bp -89 to -94 and -114 to
-121 contain consensus cAMP response element binding pro-
tein (eRE) binding sites (33, 34). The more upstream cAMP
response element overlaps with a putative activating transcrip-
tion factor (ATF) binding site (35). Potentially important con-
sensus binding sites for the early response gene Nm23 at bp
-246 (36) and the early growth response 1 gene (Egr-l) at bp
-163 (37-39) were identified. The latter site overlaps with both
an AP2 and a Sp1 binding site. The importance, abundance,
and overlapping nature of the putative transcription factor




binding sites suggest a complex regulation of IMPDH type II
gene transcription.
To evaluate the functional significance of the putative pro-
moter region in the regulation of IMPDH type II expression,
CAT reporter plasmids were constructed and transiently trans-
fected into exponentially growing Jurkat T cells. The con-
structs were derived from pBSCAT and contained the 1536-bp
genomic EcoRI fragment (position -463 to + 1073) and the
466-bp 5' EcoRIINcoI fragment (position -463 to +3) in 5'~3'
and 3'~5' orientations. Fig. 4 demonstrates that all constructs
containing the IMPDH type II 5' region have promoter activity.
The 1536-bp construct exhibited 200-fold higher activity than
did the pBSCAT vector alone. The pBS466(5'~3')CATcon-
struct manifested 70-fold and the pBS466(3'~5')CAT con-
struct 10-fold increased activity over the vector alone, demon-
strating that the 463-bp DNA fragment immediately upstream
of the human IMPDH type II gene's initiation codon functions
as a promoter upon transfection into Jurkat T cells, with sub-
stantially less activity in the reverse orientation.
Transfection of Peripheral Blood T Lymphocytes-IMPDH
type II mRNA levels and activity are strongly induced upon
activation of peripheral blood T lymphocytes (40). To determine
whether the 466-bp promoter fragment contains the elements
necessary for proliferation-dependent transcriptional regula-
tion of the IMPDH type II gene, pBSCAT, pBS466(5'~3')CAT
and pBS500dCK-CAT (41) constructs were transfected into
peripheral blood T lymphocytes prestimulated according to the
protocol of Park et al. (22). Following transfection, the T lym-
phocytes were maintained in culture medium or stimulated for
48 h with PMA and ionomycin. As shown in Fig. 5, PMA and
ionomycin stimulation induced pBS466(5'~3')CATexpression
6.5-fold over that of the nonstimulated cells. Expression from a
control construct containing the 500-bp core promoter of the
human deoxycytidine kinase gene (pBS500dCK-CAT) (41) was
not increased upon stimulation of T lymphocytes with PMA
and ionomycin, a finding consistent with the lack of prolifera-
tion-related up-regulation of dCK expression (42, 43). These
data demonstrate that the 466-bp promoter fragment contains
the elements required for at least a portion of the proliferation-
dependent induction of IMPDH type II expression.
DNase I Footprint Analysis of the 5' Region-The 5' -flanking
region of the IMPDH type II gene contains several consensus
transcription factor binding sites. In order to implicate nuclear
factors in the regulation oflMPDH type II gene expression in T
lymphocytes we examined in vitro nuclear protein binding to
the 463-bp 5'-flanking region of the gene. DNase I footprint
analysis of the coding strand using a probe spanning the entire
promoter from -463 to +3 revealed four protected regions,
designatedA-D, in the presence of Jurkat T cell nuclear extract
(Fig. 6). The extended footprint covering region A (-79 to
-101) corresponds with a consensus binding site (TGACGAA)
for the CREB family of leucine zipper transcription factors (33,
34) and is located immediately upstream ofthe proximal TATA
box (28) (Fig. 3). Protected region B extending from bp -111 to
-124 coincides with a recognition sequence (CTGACGTCAG)
for the CREB/ATF nuclear protein family (28, 33-35). Foot-
printed region C located at bp -152 through -176 (AGCTC-
CGCCCCCGC) contains overlapping consensus binding sites
for the nuclear factors AP2 (29), Egr-1 (37, 38), and Sp1 (30-
32). The most distal footprint D located at position -252 to
-281 is adjacent to a nuclear factor recognition sequence
(GGGTGGG) for the early response gene Nm23 (36).
DISCUSSION
The association of increased IMPDH enzymatic activity with
cellular proliferation and transformation has been known for
20 years, originating in observations on rat hepatoma cells (8)
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Exon -intron organization of th e human [AfPDH typ e II gene
Exon a nd intron nucl eotid e seq uence an d size wer e det erm in ed from single-st ra nded seque ncing. Th e size of intron 5 se pa ra t ing th e 4.8- and
6.8-kb clones was det ermin ed by sequence a na lys is a nd confirmed by polym er ase chain reaction analys is of ge nomic DNA using primer s located
in exon 5 a nd 6. Uppe r-case an d lower -case characte rs indicate exon a nd intron sequence. respectively. Th e ATG ini tia t ion codo n ade nine is




Sequ ence of exon-in t ron jun ctions
In t ron
5 ' -Sp lice donor :1'-Splice accepto r
5 ' -Sequen ce Size 3 '·Sequence
bp
GTCTCTGCGG
TCACCTACAA g tgcgggcc t 445 tccctcgcag TGACTTTCTC
AGACCAGGTG gtgagtatga 225 gtctcctcag GACCTGACTT
AGCAATGGCG gtgagccca t 107 tatcctgtag CTTACAGGCG
GAAAGTGAAG g tcaga aggg 327 ccctttccag AAATATGAAC
CTTGGAAGAG gtgggtgcca 657 tcccacgtag ATAATGACAA
AGCAAGAAGG g taagtccta 73 ctgaccacag GAAAGTTGCC
AGTGGTTTTG gtgagctgc t 77 cttgtcctag GACTCTTCCC
GGAGGCAATG g taaggcaag 99 ttcaccatag TGGTCACTGC
ACGCAGGAAG g taagaa t a t 1065 atctcaacag TGCTGGCCTG
GCCTCCACAG gtgaggcag t 83 ctgtccgcag TCATGATGGG
GATATTTCAG gtgggacagg 94 ctccctgcag TGAAGCTGAC
CCCAAGTCCG g tgagc t tgg 80 ccttcttcag AGCCATGATG
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Fi e. 2. Analysi s of the transcription initiation s ite of the IMPDH type II gene. A . pri mer exte nsion product produced from -Iurkat T cell
polytA ") RNA. DNA seque nce was obta ined from th e 1536 -bp EcoR I pr omoter fragm en t us ing th e identical oligonucleo t ide used for pri mer
exte ns ion ; lan es contain primer a lone; prim er an d yeast tRNA; primer . t RNA. a nd Jurk a t T cell polyfA. " ) RNA; a nd <j>X 174 D, ' f lIae'" markers.
Th e transcription initiation si te a nd sequence surro u nding th e site is indica ted on the left. B. ribonuclease protecti on assay of -Iu rka t, H L60. an d
Raji poly rA " ! RNA hybrid ized to th e 466- bp :12 P-la beled RNA template exte nding 5 ' of th e translatio n init ia t ion s ite , Lanes conta in probe plu s yeas t
tRNA; pr obe plu s polyrA " ) RNA from -Iur kat, HL60. a nd Raji cells. respecti vely; an d <t>X 174 DN Hini! markers .
a nd resu lti ng in an inten siv e se a rch for IMPDH in hibitors as
potent ial antineop lastic agents . Su ch inhibitors have been
dem onst ra ted to resul t in inhibition of cell growth and th e
induction of cellular differentiation, in conjunction with inhi -
bition of DNA synthes is directly a t t r ibutable to the depl et ion of
guanine nu cleot ides 02- 16). In addit ion, severa l in hibitors
have been found to be useful as im muno suppressiv e agent and
to inhibit th e ac t iva tio n of T lymphocytes ill vitro (44. 45 ).
These obse rvat ions underscore the potent ia l importance of th i
enzymatic activi ty in modulatin g normal cell growth . Th e re-
cent ide nt ifica t ion of two sepa ra te genes enco din g Ii\!PDH ac-
tivity (4, 5 ) a nd th e dist in ct association of increases in type II
FIG.3. Nucleotide sequence of the
466-bp EcoRIlNcoI fragment contain-
ing the 5'-flanking region of the 1M-
PDH type II gene. The adenine from the
ATG initiation codon is designated +1.
The transcription start site is indicated
by the arrow. Underlined sequences indi-
cate the four regions protected from
DNase I digestion in the presence of Jur-
kat T cell nuclear extract. Putative tran-
scription factor binding sites are indi-
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- 463 MTICTTGTAACATACACTTGTGTATCATATMAGATACCACTCTGTTICTCTIATGTAT
- 403 TCTTACTCTAGTIGTTIATIAAGAATGACAAGCACGTCTTTICAACATGTTAGTGAACAA
- 3 4 3 CGTCI CiliA~GPG:X:X:Xn::Gc:J3N:XiTIV3AIGfAAN:XX::rrcn:;rmrM
Nm23
- 2 8 3 mwerm:::OO6.OOIrrjIGe;t]'P3AGIillr~~~
AP2/Egr-1/Sp1
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FIG. 4. Functional analysis of the 5' region of the IMPDH type II gene. A, the 1536-bp EcoRI fragment extending 463 bp 5' of the
translation initiation site and 1073 bp 3' into exon 4 was subcloned into the reporter construct pBSCAT in the 5'~3' orientation. The 5' 466-bp
EcoRIlNcoI fragment was excised and subcloned into pBSCAT in both orientations. The translation initiation site is indicated by the arrow. B,
Jurkat T cells were transiently transfected with the above constructs and with the plasmid pJ3Ac-IacZ and assayed 48 h posttransfection for CAT
and J3-galactosidase activities, respectively. Chloramphenicol acetyltransferase activity was corrected for extract protein concentration. To
normalize for differences in transfection efficiencies between experiments, CAT values were standardized to J3-galactosidase values. Values
represent the mean of two independent experiments performed in duplicate. The bars indicate the SD.
IMPDH mRNA with neoplastic transformation in several cell
types (18, 19) have made it feasible to search for the molecular
basis for the regulation of expression of the type II gene at
different stages of cell development. In order to determine the
structural basis for IMPDH gene regulation, we have cloned
and characterized the type II IMPDH gene and its 5' -flanking
sequence.
Type II IMPDH is a relatively small gene of approximately
5.8 kb consisting of 14 exons varying in size from 49 to 207 bp.
The transcription initiation site, as determined by both primer
extension analysis and RNase protection, occurs 50 bp up-
stream of the ATG and 9 bp 5' to the 5' terminus of the
published cDNA (5). The 5' -untranslated region of the cDNA is
highly (70%) GC-rich. The 463-bp 5'-flanking region confers
strong promoter activity on a CAT reporter gene when trans-
fected into Jurkat T cells and peripheral blood T lymphocytes.
When T lymphocytes are stimulated with the pharmacological
agents PMA and ionomycin, promoter activity was increased by
about 6-fold; in contrast, promoter activity was unaffected
when Jurkat T cells were stimulated under the same conditions
(data not shown).
Recent studies by our group have shown that activation of
peripheral blood T lymphocytes with the mitogens PMA and
ionomycin results in a 10- and 15-fold induction oflMPDH type
II mRNA expression and total cellular enzymatic activity, re-
spectively (40). It has been suggested that the growth-regu-
lated increase in IMPDH expression is due to a posttranscrip-
tional nuclear processing event (46). However, our data suggest
that a major transcriptional component is responsible for the
up-regulation of IMPDH type II gene expression in activated
peripheral blood T lymphocytes. Although these data are not
conclusive, they strongly suggest that the 463-bp upstream





model sys te m to examine IMP DH expression as a function of T
cell activation (40). We observed the induction of IMPDH type
II mRNA withi n 6 h after st imula t ion of T lymphocytes with
PMA a nd ionornycin , as well as with phytohemagglutinin a nd
a lloge neic mononu clear cells , although maximum induction
was observed at 24 h. In addition , IMP DH type II mRNA levels
increased in response to PMA alone and to calcium ionoph ore
a lone, a lt hough the combination of PMA and ionomycin was
significa nt ly more potent than eithe r agent alone. irnilar reo
suits were obtained for Egr-l express ion; th e combina t ion of
phorb ol ester a nd ca lcium ionophore lead to higher express ion
th an eit he r age nt a lone (49). Although th e evide nce implica ting
Egr-l in IMPDH ty pe II expression is circums ta ntia l a t pres-
ent, the pr esen ce of a protected region (C) corresponding to th e
Egr -I bind ing site in the IMPDH type II prom oter a nd th e
FIG. 6. DNa se I footprint a nalysis o f t he 5 '- n a n k in g region of
t h e IMP DH type II gene. A 466-bp DNA fra gment contai ning the
IMPDH ty pe II 5 ' -flanking region was lab eled a t th e 3 ' end on the
coding st ra nd and subjected to DNase I treatment in th e a bse nce of
nuclear extract (0 ), or in th e presen ce of 120 ",g or 240 ,..g of .I urkat T
cell nuclear extract. Th e position of four regions prot ected in th e pres-
ence of nuclear ext rac t (A - D ) a re ind ica ted on th e r ight . Th e loca tion of
th e transcription sta rt site is indica ted by th e arrow .
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region contains at least a portion of th e regulatory elemen ts
necessary for the proliferation-related expression of th e gene.
While we have not ruled out a direct effect of PMA and iono-
mycin on gen e expression th at is ind ependent of proliferation ,
the lack of an effect of th ese agents on promoter-mediated CAT
expression in Jurkat T cells mak es this expla na tion less likely.
It remains possibl e th at othe r region s of th e ge ne outsid e of th e
promoter region contribute to IMPDH type II up-regulation.
Ind eed, th e 2-3-fold high er level of CAT activity found with th e
1536-bp construct containing a portion of the proximal codin g
region of the ge ne in addit ion to th e 463-bp 5 '-fla nking region
sugges t th e exis te nce of enha ncer act ivity in this region .
Several pot entially important regulatory sites in th e 463-bp
5 '-flan king region of th e gene are protected from DNase I
digestion in th e presence of Jurkat T cell nuclear ext ra ct and
suggest functional releva nce for IMPDH typ e II expression.
Th e pre sence of a consen su s bind ing site (CGCCCCCGC) for
th e transcription factor Egr-l (37, 38) (sy nonymous with Krox-
24, NGFI-A, Zif268, and T IS-8) (47) a t bp - 163 is particularly
notable. This site has been shown to bind a family of zinc finger
prot ein s that are immedi ate ea rly response ge nes important in
gr owth regu la t ion. Egr-l expression is rap idly and transiently
induced by nerve growth factor in PC12 cell s (48) and by se rum
in fibrob lasts (37, 39 ). Of particular relevance is th e observa-
tion that Egr-l is induc ed during th e GoIG l transition in th e
cell cycle after mitogenic st imula t ion of T lymphocyt es , as well
as during G 1 as a se pa ra te eve nt medi ated by interleukin-2
(49). Exposure ofT lymphocytes to an Egr -I antisense oligonu-
cleoti de blocked lymphocyt e act ivation, st rongly sugges ti ng
that Egr-l is ess ent ia l for th e expression of down stream ge nes
required for th e T lymphocyte proliferative response. In previ-














FIG. 5. Tra n scriptional r egu lntion of the IMPDH type II p r o-
m oter co ns t r u c t in r esti ng and act ivated pe ripheral bl ood T
lymphocy tes. Peripheral blood T lymphocytes were prestimul a ted as
described und er "Ma teria ls a nd Methods" a nd t ransiently transfected
wit h th e cons t ructs ind icated. Ce lls were mainta ined in med iu m in the
ab sen ce of st imula tion or t rea te d wit h 10 ng/m l PMA a nd 125 ng/ml
ionomycin and cont inue d in cu lt ure for 48 h. Cells ext rac ts were as-
sayed for CAT act ivity . S ti mulated T lymphocytes exhibite d a 2.4- fold
higher I"Hl t hymidine incorpora tio n th a n nonstimulated cells . Values
a re th e mean of a sing le ex perime nt perform ed in duplicate a nd repre-
se nt data obt ained from three ind ependen t ex perime nts . • . cont rol; fJiJ.
PMA + ionomycin .
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requirement for increased IMPDH gene expression for T lym-
phocyte activation do suggest that this site could be of consid-
erable functional importance. It should also be noted, however,
that the putative Egr-l site overlaps with sites for the tran-
scription factor AP2 (CCGCCCCCGC) (29) and Spl (GCTC-
CGCCCC) (30, 32). These overlapping sites offer the potential
for more complex regulation based on transcription factor in-
teractions. It has been observed, for example, that Egr-l can
act as a repressor of Spl activity at the coincident binding site
in the adenosine deaminase gene promoter (50).
A second region of interest in the IMPDH type II promoter is
the DNase I protected region D that occurs in close proximity to
the recognition sequence for the nuclear purine-binding tran-
scription factor Nm23 (GGGTGGG) (36). Nm23, also known as
PuF, was previously shown to bind to a nuclease hypersensitive
element of the human c-myc PI promoter and directly regulate
c-myc transcription (51). Nm23 is a nucleoside diphosphate
kinase enzyme, the phosphorylation status of which appears to
vary as a function of the metastatic potential of some cell types
(52). The transcriptional regulatory function of this protein has
been shown to be independent of its enzymatic activity (53).
Recent studies of Nm23 expression in peripheral blood lympho-
cytes have demonstrated a strong correlation between Nm23
expression and proliferative activity, with levels of Nm23 pro-
tein being significantly higher in activated peripheral blood
lymphocytes and in malignant proliferating lymphoid cells
than in resting leukocytes (54). The increase in the level of
Nm23 occurred as a relatively late event, suggesting a poten-
tial role for this protein in the late G1 and early S phases of the
cell cycle. Similarly, increased IMPDH expression has been
demonstrated to be a requirement for continued cellular pro-
liferation (12, 16). The finding that the murine homologue of
Nm23-H2 serves as a differentiation inhibiting factor in mouse
myeloid leukemia cells further supports a role for Nm23 in cell
proliferation (55). Whether or not Egr-l and Nm23 are integral
to IMPDH type II expression will be determined by specific
mutagenesis experiments. Delineation of their respective roles
should provide further insight into the cascade of molecular
events required for the ultimate synthesis of guanine nucleo-
tides necessary for the initiation of DNA replication.
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